Volume 72, Issue 1 pp. 56-60
Original Article: Gastroenterology: Inflammatory Bowel Disease

Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients

Marieke Zijlstra

Marieke Zijlstra

Department of Paediatric Gastroenterology, Wilhelmina Children's Hospital, Utrecht

Search for more papers by this author
Maria M.E. Jongsma

Maria M.E. Jongsma

Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam

Search for more papers by this author
Annick de Vries

Annick de Vries

Sanquin Diagnostic Services, Biologics Lab, Amsterdam, The Netherlands

Search for more papers by this author
Tiny Schaap

Tiny Schaap

Sanquin Diagnostic Services, Biologics Lab, Amsterdam, The Netherlands

Search for more papers by this author
Karien Bloem

Karien Bloem

Sanquin Diagnostic Services, Biologics Lab, Amsterdam, The Netherlands

Search for more papers by this author
Lissy de Ridder

Corresponding Author

Lissy de Ridder

Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam

Address correspondence and reprint requests to Lissy de Ridder, Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Wytemaweg 80, 3015 GD Rotterdam, The Netherlands (e-mail: [email protected]).Search for more papers by this author
First published: 14 August 2020
Citations: 3

Sanquin financed the trough and antibody measurements of both the venous and the dried blood spot samples.

Dr de Ridder reports grants from ZonMW, Pfizer, Celltrion, and Abbvie, outside the submitted work. For the remaining authors, none is declared.

ABSTRACT

Objectives:

Blood to measure infliximab (IFX) levels is typically obtained with venipuncture. Dried blood sampling (DBS), using capillary blood obtained from a finger prick, would be an alternative to measure IFX blood levels while being more patient friendly. The aim of this study is to compare IFX blood level measured by venipuncture versus DBS in patients with paediatric inflammatory bowel disease (PIBD) to assure accuracy.

Methods:

A prospective clinical pilot study was performed in patients with PIBD. Before IFX infusion, blood was collected simultaneously through venipuncture and DBS from a finger prick, using Mitratips (Neoteryx). All IFX concentrations were measured by an enzyme-linked immunosorbent assay. The Bland-Altman analysis was used to measure limits of agreement. The interrater reliability was measured with the interclass correlation coefficient and Cohen kappa. To calculate Cohen kappa, IFX levels were categorized into 3 groups; low <5 μg/mL, adequate 5 to 10 μg/mL, and high >10 μg/mL.

Results:

Twenty patients were included. Median age was 12.1 year (interquartile range 8–16 year). The mean difference between the 2 methods was −0.14 as calculated with Bland-Altman plot. The limits of agreement were between −1.39 and 1.12. The interclass correlation coefficient was with 0.998 excellent. The Cohen kappa between 3 IFX level categories was strong K = 0.911 (P = 0.0001). There was a strong correlation between venous IFX serum levels and DBS (r = 0.991, P = 0.0001) in the included patients.

Conclusions:

This is the first study in patients with PIBD to show that bloodspot technology is a patient friendly alternative method to measure IFX blood levels in PIBD.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.